Haslemo T - Search Results

1

Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients.

Parker K, Aasebø W, Haslemo T, Stavem K. Parker K, et al. Among authors: haslemo t. Springerplus. 2016 Mar 22;5:350. doi: 10.1186/s40064-016-1986-y. eCollection 2016. Springerplus. 2016. PMID: 27066364 Free PMC article.

2

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.

Høiseth G, Haslemo T, Uthus LH, Molden E. Høiseth G, et al. Among authors: haslemo t. Ther Drug Monit. 2015 Oct;37(5):589-93. doi: 10.1097/FTD.0000000000000183. Ther Drug Monit. 2015. PMID: 25565674

3

Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Smith RL, Haslemo T, Refsum H, Molden E. Smith RL, et al. Among authors: haslemo t. Eur J Clin Pharmacol. 2016 Sep;72(9):1099-104. doi: 10.1007/s00228-016-2087-0. Epub 2016 Jun 29. Eur J Clin Pharmacol. 2016. PMID: 27353638

4

Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker.

Hole K, Wollmann BM, Nguyen C, Haslemo T, Molden E. Hole K, et al. Among authors: haslemo t. Ther Drug Monit. 2018 Aug;40(4):463-468. doi: 10.1097/FTD.0000000000000518. Ther Drug Monit. 2018. PMID: 29649093

5

Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.

Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Haslemo T, et al. Br J Clin Pharmacol. 2019 Jan;85(1):194-201. doi: 10.1111/bcp.13788. Epub 2018 Nov 11. Br J Clin Pharmacol. 2019. PMID: 30312494 Free PMC article.

6

The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.

Kringen MK, Bråten LS, Haslemo T, Molden E. Kringen MK, et al. Among authors: haslemo t. J Clin Psychopharmacol. 2020 Mar/Apr;40(2):137-144. doi: 10.1097/JCP.0000000000001174. J Clin Psychopharmacol. 2020. PMID: 32134850

7

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.

Hole K, Haslemo T, Molden E. Hole K, et al. Among authors: haslemo t. Ther Drug Monit. 2023 Oct 1;45(5):683-688. doi: 10.1097/FTD.0000000000001096. Epub 2023 Mar 30. Ther Drug Monit. 2023. PMID: 37012633

8

Effect of CYP2D6 genotype on duloxetine serum concentration.

Hole K, Gangsø S, Jensstuen ÅT, Ormøy HH, Paulsen M, Molden E, Haslemo T. Hole K, et al. Among authors: haslemo t. Basic Clin Pharmacol Toxicol. 2024 Jan;134(1):186-192. doi: 10.1111/bcpt.13954. Epub 2023 Oct 30. Basic Clin Pharmacol Toxicol. 2024. PMID: 37864290

9

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E. Haslemo T, et al. Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20. Clin Pharmacol Ther. 2012. PMID: 22713701

10

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E. Mannheimer B, et al. Among authors: haslemo t. Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251. Ther Drug Monit. 2016. PMID: 26418700

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page